Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP plus enzastaurin versus R-CHOP in first-line diffuse large B-cell lymphoma
2008-005496-10Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enzastaurin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: progression-free survival. Started Sep 2008; status: terminated.
02
Drugs
enzastaurin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2008-005496-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005496-10.